Evidence map›Paper›PMID 41816692›Full record

ArticleFrontiers in microbiology2026

Dual-probe genome mining identifies citrulassin N, a novel citrulline modified lasso peptide from

Zi-Ru Wang, Chao Zeng, Zhang-Yuan Yan, Zi-Fei Xu, Dan Feng

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zi-Ru WangDepartment of Clinical Pharmacy, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Chao ZengDepartment of Clinical Pharmacy, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Zhang-Yuan YanState Key Laboratory of Pharmaceutical Biotechnology, Institute of Functional Biomolecules, School of Life Sciences, Nanjing University, Nanjing, China.
Zi-Fei XuState Key Laboratory of Pharmaceutical Biotechnology, Institute of Functional Biomolecules, School of Life Sciences, Nanjing University, Nanjing, China.
Dan FengDepartment of Clinical Pharmacy, Affiliated Hospital of Jiangsu University, Zhenjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lasso peptides are a structurally distinctive class of ribosomally synthesized and post-translationally modified peptides (RiPPs) featuring a threaded rotaxane topology that confers remarkable thermal stability and protease resistance. Citrulassins represent a rare subgroup of lasso peptides distinguished by a citrulline residue generated through peptidylarginine deiminase (PAD)-catalyzed deimination of arginine. Prior to the identification of citrulassin A, such a modification had not been observed in RiPPs, and notably, the PAD-encoding gene is located outside the canonical lasso peptide biosynthetic gene cluster (BGC). Methods: Here, we developed a dual-probe genome-mining strategy that integrates homology searches for both the lasso peptide cyclase (CitC) and a PAD homolog to selectively prioritize candidate producers from the IFB bacterial genome database. Guided by this strategy, fermentation and targeted isolation led to the discovery of citrulassin N (1) from Results: Comprehensive structural elucidation using NMR spectroscopy and tandem mass spectrometry confirmed citrulassin N as a novel citrulline-modified lasso peptid. Discussion: This study expands the structural diversity of citrulline-containing lasso peptides, demonstrates the utility of a dual-probe genome-mining approach for identifying RiPPs with rare post-translational modifications, and provides a practical framework for the targeted discovery of functionally decorated RiPP natural products.

Indexed as

biosynthesiscitrulassingenome mininglasso peptidesRiPPs

Identifiers

PMID41816692
PMCPMC12971885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.